Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 5/20 | 0.35 |
| ▸ | BRAF | P15056 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.33 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471365 | 0.91 | BRAF (0.33) | ABL1BRAFRAB9ASMN1; SMN2 | |
| SCHEMBL4482385 | 0.88 | BRAF (0.34) | BRAF | |
| SCHEMBL4461661 | 0.87 | ABL1 (0.40) | ABL1BRAFMAPT | |
| SCHEMBL4475007 | 0.87 | BRAF (0.33) | BRAFRAB9ASMN1; SMN2 | |
| SCHEMBL4478022 | 0.85 | RXRA (0.37) | BRAF | |
| SCHEMBL4465334 | 0.84 | NR1I2 (0.35) | BRAFL3MBTL1 | |
| SCHEMBL4501468 | 0.84 | BRAF (0.34) | BRAF | |
| SCHEMBL4484187 | 0.83 | NR1I2 (0.38) | BRAFL3MBTL1 | |
| SCHEMBL4466806 | 0.83 | BRAF (0.41) | BRAF | |
| SCHEMBL4462964 | 0.82 | BRAF (0.33) | BRAFL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511042-B2 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | claimed |
| EP-1692116-A1 | 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | claimed |
| WO-2005056535-A1 | 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| US-7511042-B2 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | IL1A, IL1R1, IL1RN | ABL1 2932/4885LMNA 4691/4885ADH5 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.